Addus Pays Up for Private Pay While the Census Clock Ticks
A $280 million AccentCare deal gives Addus density and private-pay exposure — but the organic PCS census promise has slipped again, and the stock is already up 27% in 90 days.
ADUS · Earnings Call · 2026-11-04
The beat is not the story
Addus reported a solid third quarter: revenue of $387.7 million, up 7%, adjusted EBITDA of $51.2 million, up 13.5%, and adjusted EPS of $1.83, up 17.3%. The margin line did the heavy lifting — adjusted EBITDA margin of 13.2% versus 12.5% a year ago, with G&A down to 20.7% of revenue from 21.9%. The last filed quarter showed $377 million of revenue, up 8% year over year, and 32.2% gross margin. Nothing in the P&L says the stock should be ripping.
But the tape says otherwise. Addus shares are up 27.3% over the last 90 days and sit only 5.9% below their all-time high. That is not a vote for a 7% revenue quarter. It is a vote for a changed story: private pay is now the company's top-ranked keyword, while large deal and clinical side have climbed into the top five. The market is paying for a new mix, not the old census debate.
AccentCare buys density and a different payer
The centerpiece is AccentCare. Addus signed a definitive agreement on September 14 to acquire AccentCare's personal care assets outside New York for $275 million. The business brings roughly $280 million of annualized revenue, about 13,700 average daily clients across 10 states, and a meaningfully different payer profile: private pay is roughly 7% to 8% of AccentCare versus about 2% for Addus. That is the strategic point. Private pay is less exposed to state Medicaid rate cycles, and it deepens density in Texas, Illinois, California, and Arizona while adding six new markets.
The financial trade is explicit. AccentCare's personal care business runs at a high-single-digit EBITDA margin — below Addus's corporate margin — and management thinks it can push it into the low double digits mostly through G&A savings. “they operate today probably in a high single-digit percentage EBITDA range ... opportunity to get their operations up into that low double-digit range” — Brian Poff, Chief Financial Officer · 2026-11-04. The deal is expected to close in Q1 2027; the federal antitrust review period has expired, and Addus is waiting on customary approvals.
That sets up the 2027 margin conversation.
With AccentCare coming on board, we are going to shift more toward personal care, which is a little lower profile than you see in hospice and home health. So we will expect to see that have an impact.
In plain English: revenue growth gets a 19% boost, but consolidated EBITDA margin probably comes down next year without another deal. Management is already signaling more M&A, and not just in personal care. “we anticipate being more aggressive in looking at various clinical opportunities, which we believe will present themselves over the next few quarters” — Dirk Allison, Chief Executive Officer · 2026-11-04. That is a real shift from the past few years, when Addus talked about clinical assets but mostly bought PCS density.
The census promise moves one more quarter
The organic PCS engine is still the hinge. Same-store personal care revenue rose 6.9%, but same-store hours grew only 1.6% and same-store average daily census fell 0.4%. Seven of the top 10 markets grew, yet Texas and Illinois — the two biggest — were slightly negative. Management blamed a September soft patch and said October looked more like July and August. “We saw Texas and Illinois in September flatten out just a bit ... it appears that we are back on track” — Dirk Allison, Chief Executive Officer · 2026-11-04. The guide for Q4 is flat to slightly positive census.
That is a familiar promise. On the August call, management said it hoped the second half of 2026 would deliver positive year-over-year ADC growth. “it is our hope that during the second half of 2026, we not only will continue to see sequential growth in ADC, but you will also return to the year over year growth” — Dirk Allison, Chairman · 2026-08-04. The second half is now one quarter from over, and the census is still not positive. The hours target has also slipped: on the May call, Brian Poff framed 2% to 2.5% same-store hours growth as the comfort zone. “We can keep that same-store hours per business day between 2% and 2.5%, we're probably going to be in a pretty good spot” — Brian Poff, Chief Financial Officer · 2026-05-05. Q3 came in at 1.6%.
The 2027 rate backdrop makes the volume gap more important. PCS same-store revenue growth was running well above the 3% to 5% target on state rate increases; next year, with Illinois not expected to deliver an increase early, management expects to be back in that range. “we will probably be more in that 3%-5% range the first half of next year” — Brian Poff, Chief Financial Officer · 2026-11-04. If rate support normalizes and census is still flat, the organic growth algorithm needs the caregiver app and fill rate to do more work. The census growth theme is not new — it has been the central debate for several quarters — but it remains unresolved.
Hospice, home health, and the quiet operating story
The clinical segments are smaller but healthier. Hospice same-store revenue rose 4.1%, or 8.8% excluding the prior-year implicit price concession benefit; average daily census rose 4.3% to 4,031 and exceeded 4,100 in October. Median length of stay was 25 days. Home health same-store revenue rose 2.5%, the first positive year-over-year quarter in a couple of years, with admissions up 13.8% under new leadership. The Bridge program is producing over 25% of hospice admissions from home health in New Mexico and Tennessee, and Addus is extending it to Illinois.
This is the part of the story that supports more clinical M&A. If Addus can buy home health and hospice assets at reasonable multiples, it can shift mix back toward higher-margin segments and feed the bridge program. The risk is that clinical assets have been expensive; management says multiples are moderating, but that is not the same as cheap. The HomeCare Homebase rollout is the enabling infrastructure — most states by the end of 2026, Illinois in Q1 2027, New Mexico after that, and Texas by the end of 2027.
Balance sheet, regulation, and the margin trade
Addus has plenty of room. Cash was $98.5 million at quarter-end, bank debt $24.3 million, and revolver availability $617.8 million after paying down $40 million in the quarter and another $10 million in October. The last filed quarter showed $38 million of effective net cash, a sharp reversal from the net debt position a year earlier. That balance sheet is the reason AccentCare is fundable without stress.
The watch item is receivables. DSOs rose to 39.3 days from 35.5 days, and Illinois Department on Aging DSOs jumped to 48 days from 26.8 days on normal payment timing. Receivables were 38.5% of revenue, down year over year but worth monitoring as AccentCare adds more states.
On policy, Dirk Allison expects movement on the Medicaid 80/20 rule by year-end. “we still do believe and expect by year end, we will see a movement on the 80/20” — Dirk Allison, Chief Executive Officer · 2026-11-04. Medicaid work requirements have not hurt volumes, and management sees an appropriate moratorium on new providers as a potential consolidation tailwind. The Indiana second acquisition is delayed by regulatory approvals, not the moratorium, but it is another reminder that deal timing is not fully in Addus's hands.
The story, then, is a company using its balance sheet to buy density and private-pay exposure while the organic census inflection keeps slipping. The Q3 beat is real, but it is not why the stock is near a high. The market is underwriting AccentCare, the private-pay mix, and a more aggressive clinical M&A posture. The next two quarters need to show that October's census bounce is durable and that AccentCare closes without integration slippage. If they do, Addus can grow into the multiple. If they do not, the stock has already priced a lot of the new story.